Management of Refractory Aggression in Children with ASD and ADHD

Diagnostic Reassessment and Treatment Approach

The American Academy of Child and Adolescent Psychiatry recommends reassessing the diagnosis for unmasked comorbidities, optimizing stimulant therapy, and implementing intensive parent behavioral training concurrently, before adding risperidone as an adjunctive medication if aggression persists 1, 2
The treatment approach should include identifying and addressing environmental antecedents and specific triggers for aggressive episodes, as well as evaluating for medication-induced aggression, particularly in children taking atomoxetine 1

The American Academy of Child and Adolescent Psychiatry suggests switching to or optimizing stimulant medication, such as methylphenidate or amphetamine, as the foundation of treatment, as stimulants are first-line therapy and can reduce both ADHD symptoms and aggressive behaviors in children with ASD and ADHD 1, 2
Stimulants have demonstrated stronger immediate effects on core ADHD symptoms compared to atomoxetine and can improve aggressive behaviors when ADHD is the primary driver, with effect sizes ranging from 0.39-0.52 in children with intellectual disabilities 3, 4

The American Academy of Child and Adolescent Psychiatry recommends concurrently implementing parent training in behavioral management, which is essential for addressing oppositional behaviors, aggression, and noncompliance that extend beyond core ADHD symptoms 1, 2
Parent management training and cognitive-behavioral therapy have extensive randomized controlled trial support for reducing anger, irritability, and aggression in children with ASD and ADHD 2

The American Academy of Child and Adolescent Psychiatry suggests adding risperidone as a first-line adjunctive agent if aggression persists despite optimized stimulant therapy and behavioral interventions, as it has the strongest controlled trial evidence for reducing aggression in children with ASD and comorbid ADHD 1, 2
Risperidone has demonstrated efficacy in multiple large randomized controlled trials, showing improvement in irritability and aggression within 2 weeks, sustained over 48-week extension studies, with a target dose of 0.5-2 mg/day 5, 3, 4

The American Academy of Child and Adolescent Psychiatry recommends considering divalproex sodium as a second-line adjunctive agent if risperidone is ineffective or poorly tolerated, particularly for explosive temper and mood lability, with a dosing range of 20-30 mg/kg/day divided BID-TID 1, 2
Alpha-2 agonists, such as clonidine or guanfacine, can be considered as alternative first-line agents when comorbid sleep disorders, tic/Tourette's disorder, or substance use concerns are present, with careful monitoring for side effects such as depression, sleep disturbance, sedation, cardiac disturbances, and cognitive dulling 2, 3